Cáncer avanzado de orofaringe. Nuevo paradigma de tratamiento / ADVANCED OROPHARYNGEAL CANCER TREATED WITH SEQUENTIAL CHEMORADIATION PRESERVING THE ORGAN

Antecedentes: Hasta la década del 80 los pacientes con esta patología eran intervenidos quirúrgicamente. A partir de 1997 la Cleveland Clinic publica un estudio basado en la quimioradioterapia en el cáncer avanzado de orofaringe con resultados similares a los de la época anterior, pero con preservación del órgano. En nuestro medio no existe bibliografía que analice estadísticamente los resultados y los factores que lo condicionaron. Objetivo: Evaluar los resultados con quimioradioterapia secuencial en el cáncer avanzado de la región orofaríngea. Lugar de aplicación: Hospital de atención terciaria Diseño: Prospectivo no randomizado Material y metodo: Desde Enero del 2002 al 30 de diciembre del 2004 se estudiaron 60 pacientes, 55 pertenecían al sexo masculino, con edad media de 60 años, el 76.7% eran T III y los restantes T IV con tumores malignos de la región orofaríngea mediante quimioradioterapia secuencial. Resultados: La supervivencia a 152 meses fue del 30.1%. El análisis univariado, demostró que el estadío, con p<0,001, la reducción con p=0,010 y la cirugía de rescate con p=0,028 fueron las únicas variables estadísticamente significativas, mientras la edad, el sexo y la localización no tuvieron los mismos resultados. En el análisis multivariado, el estadío con una p< 0.001, el sexo con una p=0.016 y la reducción con una p=0.024 resultaron ser estadisticamente significativos. Conclusiones: El tratamiento de los tumores de la región orofaríngea, en estadíos III y IV, mediante quimioradioterapia secuencial alcanzaron resultados similares a los tratados con cirugía seguida de radioterapia, pero con preservación del órgano

Background: Until the 80th decade, patients with advanced oropharyngeal cancer were surgically treated. In 1997 the Cleveland Clinic published similar results with chemoradiotherapy but preserving the organ. In our country there are not papers analyzing those results and conditional factors. Objective: Evaluation of sequential chemoradiation results in advanced oropharyngeal cancer Setting: Public tertiary care Hospital of tumours Design: Prospective not randomized. Population and methods: From January 2002 to December 2008, 60 patients were analysed, 55 of them were male with a mean age of 60, 76.7% TIII/IV oropharyngeal carcinomas treated with sequential chemoradiation. Results: The overall 152 months of survival was 30.1%. Univariate analize showed stage p<001, reduce of lesion p:0.010 and rescue surgery p:0.028 were statiscally significative. Age, gender and subsite had not similar results. In multivariate analize only stage p:0.001, gender p: 0.016 and reduce of lesion p:0.024 resulted statiscally significative. Conclusions: Sequential chemoradiation of III and IV stage tumours of oropharyngeal area have similar long terms results than those treated with surgery plus radiation but with organ preservation

Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.

PURPOSE: This study evaluated whether the combination of the synthetic rexinoid bexarotene with first-line cisplatin/vinorelbine therapy provides additional survival benefit in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with stage IIIB with pleural effusion or stage IV NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to open-label bexarotene 400 mg/m(2)/d with cisplatin/vinorelbine or to cisplatin/vinorelbine alone. Antilipid agents were initiated on or before day 1 in the bexarotene arm. Primary efficacy end point was overall survival. Primary, secondary and supportive efficacy analyses were conducted. RESULTS: A total of 623 patients (312 control, 311 bexarotene) were enrolled. Overall, no significant difference in survival occurred between the two treatment groups. However, an unplanned retrospective analysis showed that a subpopulation of bexarotene patients (n = 98 of 306) who experienced National Cancer Institute grade 3/4 hypertriglyceridemia had longer median survival compared with control patients (12.3 v 9.9 months; log-rank P = .08). Within that subgroup, those who benefited the most included males, smokers, those with stage IV disease, and those with a 6-month prior weight loss of 5% or more. Incidence, type and severity of grade 3/4 adverse events were comparable between arms, except for leukopenia (higher in chemotherapy arm) and hyperlipemia, hypothyroidism, dyspnea, and headache (higher in chemotherapy/bexarotene arm). CONCLUSION: The addition of bexarotene to first-line chemotherapy did not increase survival in patients with advanced NSCLC. However, a subgroup (32%) of bexarotene-treated patients developing high-grade hypertriglyceridemia appeared to have better survival (12.3 months) than controls; thus triglyceride response may be a biomarker of survival benefit with bexarotene.